Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 11Phase NA 5Phase 1/2 4Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lung Neoplasms 10Prostatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Brain Neoplasms 3Ureteral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Rhabdomyosarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Mouth Neoplasms 2Medulloblastoma 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hematopoietic and Lymphatic System Neoplasm 2Glioblastoma 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Specimen Handling × Clear all
NCT03941860 2025-05-23

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

National Cancer Institute (NCI)

Phase 3 Completed
1 enrolled 1 chart
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡